The success of ADCs has stimulated the pharmaceutical industry to explore novel drug conjugates, leading to the development of a large number of novel Conjugated Drugs in a wide variety of forms, such as peptide-drug conjugate (PDC) and immune-stimulating antibody conjugate (ISAC), etc.
